Trial Profile
A Phase II Trial of Cabozantinib (XL-184) (NSC-761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 05 Apr 2019 Status changed from active, no longer recruiting to completed.
- 05 May 2018 Results published in the Gynecologic Oncology
- 01 Nov 2016 Status changed from suspended to active, no longer recruiting.